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Abstract
This study reports the development of a sensitive magnetic bead-based enzyme-linked immunoassay (MELISA) for the pan-
reactive detection of the Influenza A virus. The assay combines immunomagnetic beads and biotin-nanoparticle-based detection
to quantify a highly conserved viral nucleoprotein in virus lysates. At the capture step, monoclonal antibody-coated magnetic
microbeads were used to bind and concentrate the nucleoprotein in samples. The colorimetric detection signal was amplified
using biotinylated silica nanoparticles (NP). These nanoparticles were functionalized on the surface with short DNA spacers
bearing biotin groups by an automated supported synthesis method performed on nano-on-micro assemblies with a DNA/RNA
synthesizer. A biotin-nanoparticle and immunomagnetic bead-based assay was developed. We succeeded in detecting Influenza
A viruses directly in the lysis buffer supplemented with 10% saliva to simulate the clinical context. The biotin-nanoparticle
amplification step enabled detection limits as low as 3 × 103 PFU mL−1 and 4 × 104 PFU mL−1 to be achieved for the H1N1 and
H3N2 strains respectively. In contrast, a classical ELISA test based on the same antibody sandwich showed detection limit of
1.2 × 107 PFU mL−1 for H1N1. The new enhanced MELISA proved to be specific, as no cross-reactivity was found with a
porcine respiratory virus (PRRSV).
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Introduction
Influenza viruses cause worldwide outbreaks and pandemics in
humans and animals with high morbidity and mortality [1]. Of
the Influenza A, B, C andD viruses, Influenza A viruses mutate
the most rapidly leading to the continuous apparition of new
strains. The high antigenic flexibility and hence greater
virulence increase the severity of illnesses and death rates in
the event of a pandemic [2]. The seasonal subtypes of circulat-
ing Influenza A viruses (H1N1 and H3N2) cause 3–5 million
human severe infections and between 290,000 and 650,000
fatal cases annually, mostly in elderly and immunocompro-
mised individuals and in the young children [3, 4]. There is
an urgent need to improve diagnostic of H1N1 and H3N2
viruses to better control future outbreaks.
Rapid diagnostic tests for influenza, mostly based on anti-
gen detection, facilitate early detection and then improve clin-
ical decision-making. Furthermore, such tests can serve as
tools for disease monitoring. Most of the assays dedicated to
rapid detection of the currently circulating subtypes of
Influenza A viruses use monoclonal antibodies (mAbs)
against the nucleoprotein (NuP) encoded by Influenza A vi-
ruses. The NuP protein is highly abundant, notably during
Influenza A virus infections [5, 6]. It is also a highly conserved
protein among the different subtypes of Influenza A viruses
with a > 90% amino acid sequence identity [7]. Thus, the
approach targeting the nucleoprotein A is generic for a large
panel of Influenza A strains. For instance, Yang et al.
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produced two monoclonal antibodies against the avian
Influenza A nucleoprotein [8]. The immunoassays targeting
NuP proved to be robust and specific for 15 subtypes of avian
Influenza A viruses. In 2020, an antibody microarray was de-
veloped from a preselection of 50 mAbs [9]. The diagnostic
system detected and differentiated six clinically important up-
per respiratory tract pathogen groups, including Influenza A
and B viruses, by testing 25 mAbs against the nucleoprotein.
The first ELISA test based on immunocapture of the nucle-
oprotein was described by Chomel et al. [10]. This
immunocapture sandwich assay was found to be specific for
a large panel of human and animal influenza viruses and no
cross-reaction with other respiratory viruses was observed. A
minimal amount of 5 ng mL−1 of purified viral NuP was de-
tected using highly sensitive radioactive detection [11]. In
2010, Chen et al. developed the Flu A DOT ELISA [12].
This test kit, which targets NuP in real samples of viruses,
showed high sensitivity compared with the commercial kit
QuickVue Flu A from Quidel Corp. and sufficient specificity
for all the variants of the Influenza A virus considered (LoD:
1.6 × 103 TCID50 mL
−1 for the H5N1 strain). A one-step im-
munoassay with interferometric measurement was developed
for the real-time detection of Influenza A nucleoprotein in sam-
ples [13]. The technique enabled a level of detection of
1 μg mL−1 NuP. This work aimed at developing a rapid and
portable sensor for in situ detection of Influenza A viruses.
More recently, a highly sensitive fluorescent europium nano-
particle (NP)-based immunoassay, ENIA, was developed by
Zhang et al. [14]. ENIA proved to be accurate in real samples
infected with both Influenza A and B viruses. It demonstrated
an analytical sensitivity of 2.5 × 102 EID50 mL
−1 for the
A/Brisbane/59/07 H1N1 strain. Leirs et al. screened commer-
cial antibodies against the Influenza A nucleoprotein using a
digital ELISA microscopic approach. This imaging technique
on the microscale proved ultra-sensitive for detecting the re-
combinant InfluenzaA nucleoprotein spiked in buffer, reaching
femtomolar detection limits. On the other hand, digital ELISA
showed lower efficacy for purified viruses directly in the lysis
buffer [15]. A horseradish peroxidase (HRP)-labeled lateral
flow immunoassay (HRP-LFIA) was recently developed for
simultaneous detection of Influenza A and B viruses [16].
Four monoclonal antibodies, recognizing specific epitopes in
nucleoproteins A and B, were evaluated. Compared with the
real-time RT-PCR kit for diagnosis, HRP-LFIA was found to
be sensitive and specific for the detection of Influenza A and B
viruses [16]. No cross-contamination was observed with other
common viral pathogens. In another study, several europium
detection-based LFIAs were evaluated and showed good per-
formance in comparison to the RT-PCR test [17]. Although
conventional LFIA is simple to perform and provide rapid tests
at a low cost, most LFIAs produce only a qualitative result
(positive or negative) and are not really sensitive. To improve
the performance of the assay, a microfluidic-based LFIA was
recently developed [18]. The device enabled a LoD of
0.1 ng mL−1 NuP but its use requires high technical skills.
In this paper, we present a sensitive and easy-to-use mag-
netic bead-based enzyme-linked immunoassay (MELISA) for
detecting the Influenza A virus in a clinical setting (saliva). A
magnetic bead-based immunoassay for detection of the
Influenza A virus via the nucleoprotein A has already been
described in the literature [19–21]. A fluorescence immuno-
assay (FIA) together with a magnetic concentration was inte-
grated into a microfluidic module and proved highly sensitive
and selective for detecting the Influenza A/H1 and Influenza
A/H3 viruses [20]. The microfluidic system afforded a 1000-
fold increase in sensitivity compared with a standard
immunomagnetic-based FIA carried out according to a man-
ual protocol. The LoD was 5 × 10−4 HAU in 45 μL, which
corresponds approximately to 104 PFU mL−1 [22]. Although
the assay demonstrated rapid and sensitive detection of the
Influenza A infection, it was based on the use of a
microsystem whose complex geometry makes it complicated
and challenging to manufacture. HRP-LFIA associated with a
preconcentration step of the NuP protein by magnetic beads
improved 100-fold the sensitivity [21]. The LoD was
4.7 μg mL−1. Recently, Wu et al. developed a wash-free assay
based on magnetic particle spectroscopy (MPS) and the self-
assembly of magnetic NP to quantitatively detect H1N1 NuP
[23, 24]. This rapid protocol reached the LoD of 0.25μgmL−1
for NuP and 250 TCID50 mL
−1 for Influenza A virus.
The biosensor sensitivity is of great importance to detect
pathogens in environmental, agrifood, or biological samples
because pathogens are typically present in very low concentra-
tions. Therefore, various diagnostic assays using functionalized
nanoparticles to amplify the signal and boost the sensitivity
have been reported in recent years [25–28]. Herein, we propose
to evaluate the sensitivity increase of MELISA for Influenza A
detection via the nucleoprotein A, using immunomagnetic
beads for the capture step and biotin-coated nanoparticles
(biotin-NP) to enhance the signal at the detection step.
MELISA is based on a simple operating process that is easy
to implement. It only requires magnetic beads and biologics to
elaborate the different reagents. In addition, it achieves good
sensitivities compared to other microsystems such as lateral
flow assays, and the immunomagnetic extraction allows direct
analysis of biological samples. We selected a couple of com-
mercial anti-nucleoprotein A antibodies to construct the
sandwich assay. The monoclonal antibody 9G8 is a mouse
monoclonal antibody that recognizes the NuP of the
Influenza A virus [29]. This antibody was used to
functionalize magnetic beads. The monoclonal antibody
5D8 showed broad reactivity against Influenza A subtypes
H1, H2, H3, H5, H7, and H9, and no cross-reactivity to-
wards Influenza B and other respiratory viruses [30]. The
latter was biotinylated to complete the sandwich test before
HRP colorimetric detection.
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The MELISA was carried out with a Streptavidin-HRP
conjugate to detect purified NuP in buffer. We then used
biotin-NP to amplify the signal for virus detection in complex
matrices. Experiments were performed in the lysis buffer
complemented with saliva to simulate clinical samples.
Fifty-nanometre-diameter silica NP were functionalized via
phosphoramidite chemistry, using a strategy of supported syn-
thesis, adapting a protocol previously described by our group
[31]. This well-controlled and reproducible method proved
effective for NP functionalization with methylene blue-
modified oligonucleotides [25] and proteins [32]. We used
commercia l b iot in phosphoramidi te for th is NP
functionalization. Then, the MELISA protocol with biotin-
NP was optimized for nucleoprotein detection in virus sam-




Bovine serum albumin (BSA), Bradford reagent, ELISA
Colorimetric TMB (3,3′,5,5′-tertamethylbenzidine) reagent,
Tween 20, Streptavidin-HRP, 1,8-Diazabicyclo[5.4.0]undec-
7-ene (DBU), ELISA 5X Assay/Sample Diluent buffer B and
high-quality grade chemicals were purchased from Sigma-
Aldrich (Saint Quentin Fallavier, France). Phosphate-
buffered saline (PBS) 10× was provided by Dominique
Dutscher (Brumath, France). Sodium chloride was purchased
from Laurylab (Brindas, France). Buffers were made with
deionized water and sterilized by 0.22-μm filtration.
Dynabeads®M-280 Tosylactivated and DSB-XTMBiotin
Protein Labelling Kit (D-20655) were obtained from
Invitrogen and Molecular Probes, respectively (Thermo
Fisher Scientific, Waltham, MA, USA). Influenza A NuP
(9G8) and (5D8) antibodies were from Santa Cruz
Biotechnology (St. Cruz, CA, USA). Rhodamine-coated sil-
ica nanoparticles were provided by Nano-H (Saint Quentin
Fallavier, France). Oligonucleotides were synthetized using
an Applied Biosystems 394 DNA/RNA synthesizer
(Applied Biosystems, Foster City, CA). Phosphoramidite
s y n t h o n s : B i o t i n - T EG - p h o s p h o r am i d i t e ( 1 -
dimethoxytrityloxy-3-O-(N-biotinyl-3-aminopropyl)-
triethyleneglycolyl-glyceryl-2-O-(2-cyanoethyl)-(N,N-
diisopropyl)-phosphoramidite); Spacer phosphoramidite 9
(9 -O-d ime thoxy t r i t y l - t r i e t hy l ene g lyco l , 1 - [ ( 2 -
cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite); dT-CE
p h o s p h o r a m i d i t e ( 5 ′ - d i m e t h o x y t r i t y l - 2 ′ -
deoxythymidine,3′-[(2-cyanoethyl)-(N,N-diisopropyl)]-
phosphoramidite) and all synthesis reagents were purchased
from Glen Research (Sterling, Virginia).
Saliva collection
Saliva samples were collected from healthy volunteers after
thorough rinsing of the mouth with water no less than 1 h after
a meal. Collection of saliva was carried using a 1.5-mL tube
and diluted with PBS buffer. Saliva samples were stored at −
20 °C before use.
Scanning electron microscopy
Scanning electron microscopy (SEM) was performed on mag-
netic beads at an acceleration voltage of 5 kV using a VEGA
TESCAN SEM. Before analysis, samples were metallized
with 5 nm thickness of gold.
Transmission electron microscopy
Transmission electron microscopy (TEM) was performed on a
Philips CM120 instrument operating at an acceleration voltage
of 120 kV (Centre Technologique des Microstructures, Lyon).
Silica NP were observed after deposition of 5 μL of diluted
solution on a formvar-carbon-coated copper grid and evapora-
tion to dryness.
Nucleoprotein expression and production
The full-length nucleoprotein (NuP) gene of the H1N1 (strain
A/WSN/33) influenza virus with a 6-His-tag at its C-terminal
was cloned in the Escherichia coli expression vector pET22
(Novagen) and expressed in the BL-21 Rosetta DE3 E. coli
cells (Stratagene) [33]. Transformed cells were grown at
37 °C in 100 mL of Luria Bertani medium containing ampicil-
lin to mid-exponential phase and then induced for 4 h by
adding 1 mM isopropyl-β-D-thiogalactopyranoside at 37 °C
under shaking. NuP purification was performed as previously
described [33]. Briefly, after centrifugation, the bacterial pellet
was resuspended in a lysis buffer (20 mM Tris at pH 7.4 with
NaCl (50 mM or 300 mM), 5 mM imidazole, 1% Triton and
1 mg mL−1 lysozyme), sonicated and treated with
0.15 mg mL−1 RNAse A at 35 °C for 20 min in the presence
of 10 mM Mg2+ ions. The protein was purified by affinity
chromatography using Ni magnetic beads (PureProteome,
Millipore), following the procedure recommended by the man-
ufacturer. The NuP was then dialysed against Tris buffer
(20 mM Tris, 300 mM NaCl, pH 7.5). After dialysis, the pro-
tein concentration was determined using a molar extinction
coefficient ε of 56,200 M−1 cm−1 at 280 nm.
Viral strains
Influenza A/WSN/33 (H1N1), Influenza A/UDORN/72
(H3N2) and Porcine Reproductive and Respiratory Syndrome
virus (PRRSV) Flanders13 (13V09) viruses inactivated by
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binary ethylenimine (BEI) were kindly provided byDr. Nicolas
Bertho (INRAE, France) and Dr. Fanny Blanc (INRAE,
France). All inactivated viruses were stored at − 80 °C.
Before inactivation, virus concentrations were determined in
terms of MDCK cell infection. The initial titres of the viruses
were 108 PFU mL−1 for H1N1 sample 1, 1.5 × 108 PFU mL−1
for H1N1 sample 2 and 108 PFU mL−1 for H2N3. The control
virus PRRSV was titrated at 107 PFU mL−1.
Magnetic bead functionalization
Tosyl activated magnetic beads of 2.8 μm diameter
(Dynabeads™ M-280, Invitrogen, USA) were coated with
10 μg of Influenza A NuP (9G8) antibody per milligram of
beads for 1 h under gentle shaking, according to the protocol
recommended by the manufacturer. Then, after 15 min pas-
sivation in BSA buffer (0.1 M sodium phosphate, 150 mM
sodium chloride, 0.5% (w/v) BSA, pH 7.6), the magnetic
beads were washed three times in 0.01 M sodium phosphate,
150 mM sodium chloride, 0.1% (w/v) BSA, pH 7.4, and
stored at 4 °C until the assays.
Biotin coating on silica NP
Rhodamine-coated silica nanoparticles were functionalized by
a supported synthesis strategy developed by our group [31].
The functionalization was achieved in a DNA/RNA synthesiz-
er using phosphoramidite chemistry. First, dT10-PEG2-dT10
was synthesized via the 1 μM coupling program of the instru-
ment, reaching an average phosphoramidite coupling yield per
cycle of 98%; then, the biotin group was incorporated with a
10% coupling yield. Biotin incorporation was monitored at
498 nm using dimethoxytrityl quantification by a UV-visible
spectrophotometer.
Nanoparticles were then released from the CPG by incubat-
ing the support in 1mL of DBU (1,8-Diazabicyclo[5.4.0]undec-
7-ene) 0.1% (w/v) in water-acetonitrile 1/1 (v/v). The DBU
solution was stirred in a thermomixer at 22 °C for 1 h before
recovering. A fresh DBU solution was added to the CPG sus-
pension every hour. The released nanoparticles were washed
with water (1× 4 mL then 3× 2 mL) and concentrated by cen-
trifugation on a 30K Amicon Ultra filter (5000 g, 10 min). After
the release kinetics, the nanoparticle concentration in each solu-
tion was quantified by UV-visible measurement at 560 nm (see
Supplementary Information (ESM) Fig. S1A and B). Finally,
the NP were characterized by DLS (ESM Fig. S2).
Biotin functionalization of Influenza A NuP (5D8)
antibodies
The DSB-XTM Biotin Protein Labelling Kit (D-20655) was
used. One hundred microlitres of 0.1 mg mL−1 5D8 antibody
solution and 10 μL of 1 M sodium bicarbonate solution were
transferred to a reaction tube. One microlitre of DSB-X biotin
succinimidyl ester in DMSO solution was added. The reaction
mixture was stirred for 90 min at RT. The biotinylated antibody
was then purified on a purification resin by centrifugation.
ELISA protocol for Influenza A nucleoprotein
detection
Fifty microlitres of 4 μg mL−1 solution of Influenza A NuP
(9G8) antibody in PBS buffer was added to each well of a
microtitration plate and incubated overnight at 4 °C. The wells
were washed three times using Washing buffer 0.5 (PBS,
0.5% (v/v) Tween 20, pH 7.4). Three hundred microlitres of
PBS buffer with 5% (w/w) milk was added to each well and
incubated at 37 °C for 1 h under gentle shaking. Then, the
wells were washed three times usingWashing buffer 0.5. Fifty
microlitres of Influenza A nucleoprotein in PBS buffer at dif-
ferent concentrations was added to each well, and the solu-
tions were incubated at room temperature for 2 h under gentle
shaking. Then, the wells were washed three times using
Washing buffer 0.1 (PBS, 0.1% (v/v) Tween 20, pH 7.4).
Fifty microlitres of 0.5 μg mL−1 biotinylated Influenza A
NuP (5D8*) antibody in PBS with 0.1% Tween 20 and
0.1% BSA was added before incubation at RT for 2 h. Then,
the wells were washed three times using Washing buffer 0.1.
One hundred microlitres of 1 μg mL−1 Streptavidin-HRP rev-
elation solution was added to the wells before incubating for
45 min at room temperature under gentle shaking. The wells
were washed three times with Washing buffer 0.1 before
adding 100 μL of TMB and incubating the plate in the dark
for 30 min at RT. Then, 100 μL of 2 M sulfuric acid was
added to the wells to stop the reaction. Absorbance was mea-
sured at 450 nm and 550 nm. The absorbance values retained
were A450nm–A550nm to take into consideration the optical im-
perfections of the plate.
MELISA protocol for Influenza A nucleoprotein
detection
1 × 106 magnetic beads previously coated with the Influenza
A NP (9G8) antibody were first washed with PBS buffer three
times. Nucleoprotein solutions were incubated with the beads
under gentle shaking at room temperature for 1 h. The beads
were then washed three times with Washing buffer 0.1 (PBS,
0.1% (v/v) Tween 20, pH 7.4). Conjugated biotin antibody
5D8* (0.5 μg mL−1) was incubated in a Capture buffer
(PBS, 0.1% (v/v) Tween 20, 0.1% BSA (w/w), pH 7.4) for
1 h under gentle shaking. After three washing steps,
Streptavidin-HRP revelation solution was added before incu-
bation at room temperature for 30 min at 1000 rpm in a
thermomixer. The beads were washed three times with
Washing buffer 0.1 before adding 100 μL of TMB and incu-
bating in the dark for 30 min at RT. Finally, the supernatant
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was diluted with 100 μL of 2 M sulfuric acid and absorbance
was read at 450 nm in a microplate reader (Perkin Elmer).
A450nm–A550nm gave the correct value after suppression of
the background signal.
MELISA protocol for deactivated virus detection
1 × 106 magnetic beads previously coated with the Influenza
A NP (9G8) antibody were first washed with PBS buffer three
times. Deactivated virus solutions (PBS, 10% saliva) were in-
cubated with the beads under gentle shaking at room tempera-
ture for 1 h. The beads were concentrated bymeans of amagnet
and washed three times with Washing buffer 0.1. Conjugated
biotin antibody 5D8* (0.5 μg mL−1) was added to the suspen-
sion in a Capture buffer (PBS, 0.1% Tween 20, 0.1% BSA)
before shaking gently for 1 h. After three washing steps,
Streptavidin-HRP revelation solution (100 μL, 1 μg mL−1)
was added and the mixture was shaken at RT for 30 min at
1000 rpm in a thermomixer. The beads were washed three
times with Washing buffer 0.1 before adding 100 μL of
TMB and incubating in the dark for 30 min at RT. Finally,
absorbance was read at 450 nm as previously described.
For the MELISA protocol using biotin-NP amplification,
the same protocol was used for the antigen capture. Then, the
two following steps were added for detection: biotin-NP (1 ×
1011 NPmL−1 in PBS, 0.1% (v/v) Tween 20) was added to the
magnetic bead suspension before incubation for 30 min at
1000 rpm in a thermomixer. After three washing steps,
Streptavidin-HRP revelation solution (100 μL, 1 μg mL−1)
was added before incubating the suspension at room temper-
ature for 30 min at 1000 rpm in a thermomixer. The beads
were washed three times with Washing buffer 0.1 before
adding 100 μL of TMB and incubating in the dark for 5 min
at room temperature. Finally, absorbance was read at 450 nm
as previously described.
Results and discussion
We first compared the performance of a magnetic bead-based
immunoassay calledMELISAwith that of a more convention-
al ELISA for specific detection of the Influenza A nucleopro-
tein. Figure 1 illustrates the two strategies.
ELISA detection of NuP protein
A sandwich ELISA method for Influenza A nucleoprotein
detection was performed using Streptavidin-HRP colorimetric
detection. The assay was carried out with (1) the anti-
Influenza A NuP antibody (9G8) for microwell coating and
(2) the anti-Influenza A NuP biotinylated antibody (5D8*) as
second antibody for detection. The experiments were carried
out within a range of NuP concentrations from 0 to 8μgmL−1.
9G8 and 5D8* antibodies were kept constant at 4 μg mL−1
and 0.5 μg mL−1 respectively, concentrations which have
been determined as suitable to obtain a measurable signal.
A positive control was performed in a well directly coated
with 0.5 μg mL−1 of biotinylated antibody (5D8*). A strong
colorimetric response was observed. A negative control with
no 9G8 antibody coating on the bottom of the well and a blank
corresponding to the full assay without the protein in the bind-
ing solution were also carried out.
The results are reported in Fig. 2. A detection threshold of
0.6 ODwas determined, corresponding to the average of three
blank values plus three times the standard deviation. A LoD of
0.25 μg mL−1 for NuP was obtained with this ELISA format.
MELISA detection of NuP protein
The first step in the MELISA sandwich assay consisted of
grafting the 9G8 antibody onto magnetic beads. Then, passiv-
ation of the bead surface was performed with BSA to reduce
the signal-to-noise ratio. After grafting, the number of beads
used for the assay was calculated considering the concentra-
tion of 9G8 antibody grafted to the beads, so a volume of
beads containing the same amount of the 9G8 antibody as that
used to coat the wells of the ELISA plate was used for each
assay. 1 × 106 magnetic beads were therefore used at the cap-
ture step for each test. BSA was added to PBS to improve the
washing steps and obtain the best signal-to-noise ratio.
The MELISAs were carried out by varying the Influenza A
NuP concentration from 0 to 4 μg mL−1 and the obtained data
were compiled and averaged (Fig. 3). The capture step was
performed with magnetic beads previously functionalized
with the monoclonal antibody (9G8). After NuP capture, the
detection step consisted of a second binding operation with
biotinylated 5D8* mAb and Streptavidin-HRP.
MELISA shows a strong response correlated with NuP
detection. In the protocol, the beads were incubated with
NuP protein solutions for 60 min. A plateau was reached at
0.5 μg mL−1 of protein. A detection threshold of 1.4 OD was
determined, corresponding to the average of the three blank
values plus three times the standard deviation. The results with
MELISA show a NuP detection limit of 0.063 μg mL−1,
which is 4 times better than with ELISA. A range of linearity
was observed between 0.063 and 1 μg mL−1 of NuP. The
detection limit of MELISA is also better than that obtained
byWu et al. using magnetic nanoparticles and direct measure-
ment by spectroscopy (LoD of 0.25 μg mL−1) [23] .
To optimize the time required to carry out the complete
MELISA, we also investigated MELISA with different NuP
and antibody incubation times. Incubation times of 30 min
and 60 min were investigated to bind the capture antibody
(9G8) with the NuP and the NuP with the second antibody
(5D8*). The results are shown in Fig. S3 (see ESM). With a
detection threshold calculated at 1.4 OD, the LoD reached by
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the faster test (incubation time of 30 min) was the same as that
previously obtained (0.063μgmL−1). However, the saturation
plateau was reached more rapidly. The test response after 30-
min incubation was more like a yes/no answer than a NuP
concentration-dependent response. No progressive increase
of the signal as a function of protein concentration was ob-
served. This can be explained by a steric hindrance effect that
impacted the kinetics. The binding reaction that occurs on the
magnetic bead surface takes longer than that in solution.
Considering these results, we preferred to maintain an incuba-
tion time of 60 min for the following experiments with detec-
tion of whole Influenza viruses.
MELISA detection of H1N1 and H2N3 viruses
To determine MELISA performance for Influenza A virus
detection, two different strains, H1N1 and H3N2, were stud-
ied, together with PRRSV, a porcine virus, whose nucleopro-
tein is not recognized by the antibodies.
ELISA was first performed with the H1N1 sample 1, fol-
lowing the protocol used for Influenza A NuP detection.
Different dilutions of the mother solution of the virus were
tested to estimate the lowest virus concentration that could be
detected. The blank run with PBS instead of the virus gave a
signal threshold (average of three blanks plus three times the
standard deviation) of 0.5 OD. As shown in Fig. 4, ELISA
obtained a LoD of 1.2 × 107 PFU mL−1 for H1N1 sample 1.
The same sample was then analysed by MELISA (green
curve, Fig. 4). The protocol was the same as for Influenza NuP
detection. The detection threshold of 0.5 OD was determined
as the average value of three blanks plus three times the stan-
dard deviation. MELISA shows a LoD of 2 × 105 PFU mL−1
for H1N1, which is approximatively 60 times more sensitive
than with ELISA. As for the assays with purified NuP,
MELISA increases the sensitivity of the assays run with whole
viruses. MELISA was also carried out with different
Fig. 1 Presentation of the ELISA
and MELISA for NuP detection
Fig. 3 MELISA detection of Influenza A NuP. Absorbance (Abs
450 nm–Abs 550 nm) versus 0–4 μg mL−1 of Influenza A nucleoprotein
in PBS buffer, pH 7.4. Values are mean ± SD of three independent
experiments
Fig. 2 Influenza A NuP detection by ELISA. Absorbance (Abs 450 nm–
Abs 550 nm) versus 0–8 μg mL−1 of Influenza A nucleoprotein in PBS
buffer, pH 7.4. Values are mean ± SD of three independent experiments
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concentrations of H3N2 (blue curve, Fig. 4). As expected, a
positive response was observed above a detection limit of 3 ×
106 PFU mL−1. MELISA shows good sensitivity for H1N1
and H3N2 detection but lacks sensitivity compared with the
other immunomagnetic bead-based assays described in the
literature [20, 34, 35]. The negative responses obtained for
non-related PRRSV at different concentrations indicate the
selectivity of MELISA for Influenza A viruses (Fig. 4).
Biotin-NP MELISA for Influenza A virus sensitive
detection
To enhanceMELISA’s performance and push detection limits
even further, we developed biotin-NP to amplify the positive
signal at the detection step, as illustrated on Fig. 5.
Biotin-NP development
Silica nanoparticles of 50 nm diameter were functionalized on
surface with an oligonucleotidic strand bearing a biotin group
at its extremity. The method used for NP functionalization
was based on a solid-phase synthesis technology previously
reported by our group [31]. Nanoparticles (NP) were first
immobilized on a control pore glass (CPG) support. The
resulting assembled nano-on-micro (NOM) support was char-
acterized by scanning electronmicroscopy (SEM) as shown in
Fig. S4 (see ESM). The images show that the NP are grafted
densely and homogeneously on the surface of CPG. Then, the
NOM material was used in a DNA/RNA synthesizer to per-
form NP functionalization via phosphoramidite chemistry.
This strategy provided highly functionalized nanoparticles.
An oligonucleotidic spacer (ODN sequence: dT10-PEG2-
dT10) was synthesized on the NP in order to distance the
biotins from the NP surface. Around 5000 ODNs per NP were
estimated by measuring UV absorbance at 260 nm and
560 nm and quantifying the ODN per NP ratio in the suspen-
sion, a protocol described by Bonnet et al. [25]. Then, the
biotin group was incorporated. We decided to control the syn-
thesis program on the instrument to obtain a 10% coupling
yield for biotin incorporation. Using this strategy, we incor-
porated around 50 biotins per NP. This amount was optimized
to achieve efficient binding of the biotin group during the
MELISA. After NP release from the CPG support by DBU
treatment and washing in water, the number of NP in the
resulting suspension was estimated from the fluorescent NP
quantification curve (ESM Fig. S1C, D). The NP structure
after release was controlled by TEM (Fig. 6a). This observa-
tion showed that NP morphology remained stable during
synthesis.
We also confirmed the accessibility and reactivity of the
biotins grafted onto the NP surface by SPR, via the biotin/
avidin interaction. After immobilization of avidin on a SPR
Fig. 4 MELISA and ELISA with whole viruses of different strains
(H1N1 sample 1, H3N2, PRRSV). Absorbance (Abs 450 nm–Abs
550 nm) for different concentrations of viruses (1 × 104–1 ×
108 PFU mL−1) in PBS buffer, pH 7.4
Fig. 5 Presentation of MELISA
(a) and Biot-NP MELISA (b) as-
says for Influenza A virus
detection
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chip coated with a polyelectrolyte multilayer, we managed to
observe the specific capture of the biotinylated nanoparticles
(ESM Fig. S5A). The NP specific anchoring on the avidin-
functionalized SPR chip was also confirmed by fluorescence
optical microscopy (surface in red on the picture, see ESM
Fig. S5B).
Biotin-NP display by electronic microscopy
The magnetic beads used during the biotin-nanoparticle and
immunomagnetic bead-based assay (Biot-NP MELISA) were
analysed by SEM.
For this experiment, the complete assay was carried out in
the presence of nucleoprotein (0.25 μg mL−1) at the capture
step (Fig. 6b). For comparison, a control was performed with
PBS at the capture step (Fig. 6c). The images clearly show
nanoparticles of the expected size of 50 nm decorating the
magnetic bead surface in the positive assay carried out with
the target protein. This confirms the selectivity of the assay,
with efficient binding of the biotin-NP on the magnetic beads
through the NuP present in the sample.
Influenza A virus detection in a clinical setting
The biotin-nanoparticle and immunomagnetic bead-based as-
say (Biot-NP MELISA) was investigated for detection of
H1N1 (samples 1 and 2), H3N2 and PRRSV viruses (Fig. 7).
To mimic clinical samples, the viral solutions were diluted
in lysis buffer supplemented with 10% saliva. After the sand-
wich part of the assay with viruses, the detection step was
Fig. 6 (a) TEM images of Biot-
NP; SEM images of magnetic
beads after the Biot-NP MELISA
test (b) assay with 0.25 μg mL−1
nucleoprotein; (c) blank assay
with PBS
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carried out using highly biotinylated nanoparticles to increase
the anchoring efficiency of the Streptavidin-HRP. This strategy
provided a signal increase in the case of a positive response
(Fig. 7). This improved sensitivity demonstrated the efficiency
of the amplification strategy. Detection limits of 3 ×
103 PFUmL−1, 6 × 104 PFUmL−1 and 4 × 104 PFUmL−1 were
calculated for H1N1 sample 1, H1N1 sample 2, and H3N2,
respectively. Use of biotin-NP at the detection step improved
MELISA’s sensitivity by a factor of 65 to 75. Detection limits
below 104 PFUmL−1 and 105 PFUmL−1 were achieved for the
H1N1 and H3N2 strains respectively, in the presence of 10%
saliva to simulate a clinical setting. Good selectivity of the
strains was also confirmed by the negative responses observed
at different concentrations of PRRSV (Fig. 7).
The biotin-functionalized silica nanoparticles used in this
work allowed a strong detection signal enhancement in
MELISA immunological tests, which could fulfill the detection
requirements for Influenza A virus in saliva. The excellent
reproducibility, accuracy and practicability of the proposed as-
say obtained in samples comparable to clinical indicate the
considerable potential of the present strategy. Biotin highly
functionalized silica nanoparticles could be easily adapted to
be a component of a variety of kits for detection of different
analytes (DNA, enzyme, IgG, biomarkers). In addition, biotin-
NP can be additionally functionalized to enable single step
detection. For instance, this can be obtained with attaching
organic dye-decorated antibodies or streptavidin-
functionalized quantum dots conjugated to biotinylated anti-
bodies. Overall, this technology is not limited to streptavidin
directly labeled with HRP but could also work with labeled
fluorophores via the streptavidin-biotin recognition.
Conclusions
In this study, a sensitive immunomagnetic bead-based assay
(MELISA) was developed for Influenza A virus pan-reactive
detection. The test was first compared with the standard
ELISA and showed a significant improvement in sensitivity
thanks to the magnetic capture and concentration of the target
nucleoprotein. Then, we developed a new MELISA (Biot-NP
MELISA) based on the use of biotin nanoparticles for signal
amplification at the detection step and succeeded in detecting
Influenza A/H1 and A/H3 viruses in a clinical setting. We
demonstrated that biotinylated nanoparticles further increased
sensitivity by a factor of 65–75. Detection limits of 3 ×
103 PFU mL−1 and 4 × 104 PFU mL−1 were achieved for the
H1N1 and H3N2 strains respectively. Biot-NP MELISA sen-
sitivity appears competitive compared with other immunoas-
says developed with magnetic concentration at the capture
step [20]. Our strategy allows capture of the viral nucleopro-
tein directly in solutions mimicking clinical samples, which is
a huge advantage when developing assays with a fast time-to-
result.
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